Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jan;196(1):e1-e3.
doi: 10.1111/bjh.17756. Epub 2021 Aug 1.

Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia

Paul Saultier  1   2 , Laetitia Ninove  3 , Sarah Szepetowski  1 , Mathilde Veneziano  1 , Sandrine Visentin  1 , Vincent Barlogis  1 , Paola Mariela Saba Villarroel  3 , Abdennour Amroun  3 , Marie Loosveld  4 , Xavier de Lamballerie  3 , Hervé Chambost  1   2
Affiliations
Case Reports

Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia

Paul Saultier et al. Br J Haematol. 2022 Jan.
No abstract available

Keywords: COVID-19; COVID-19 drug treatment; SARS-CoV-2; hematologic neoplasms; monoclonal antibodies.

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests to disclose.

Figures

Fig 1
Fig 1
Evolution of the clinical, haematological, immunological and viral parameters over the course of the treatment. Top panel: Evolution of the leukocyte, neutrophil and lymphocyte levels over the course of the treatment. The timepoint of administering the monoclonal antibodies bamlanivimab and etesevimab is indicated by the red arrow. The timeframe of administering the anti‐leukaemia treatment (steroids and chemotherapy) is shown in purple and orange, respectively. Middle panel: Anti‐S1 antibodies were quantified using an ELISA kit: Anti‐SARS‐CoV‐2 QuantiVac (IgG) [Euroimmun, Lübeck, Germany (binding antibody units per ml)]. Anti‐RBD antibodies were quantified using an Access SARS‐CoV‐2 IgG II Reagent Kit [Beckman Coulter Brea, CA, USA (arbitrary units per ml)]. Viral neutralizing titers were quantified as previously described. Bottom panel: SARS‐CoV‐2 RT‐PCR results based on nasopharyngeal samples (multiplex TaqPath COVID‐19; ThermoFisher Scientific, Waltham, MA, USA). The red and green dots indicate positive and negative tests, respectively. Ct, cycle threshold; ELISA, enzyme‐linked immunosorbent assay; mAbs, monoclonal antibodies; RDB, receptor‐binding domain; RT‐PCR, real‐time polymerase chain reaction; VNT, viral neutralizing titer.
See this image and copyright information in PMC

References

    1. Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID‐19: a systematic review and meta‐analysis of 3377 patients. Blood. 2020;136:2881–92. - PMC - PubMed
    1. Meena JP, Kumar Gupta A, Tanwar P, Ram Jat K, Mohan Pandey R, Seth R. Clinical presentations and outcomes of children with cancer and COVID‐19: a systematic review. Pediatr Blood Cancer. 2021;68:e29005. - PMC - PubMed
    1. Hurt AC, Wheatley AK. Neutralizing antibody therapeutics for COVID‐19. Viruses. 2021;13:628. - PMC - PubMed
    1. Avanzato VA, Matson MJ, Seifert SN, Pryce R, Williamson BN, Anzick SL, et al. Case study: prolonged infectious SARS‐CoV‐2 shedding from an asymptomatic immunocompromised individual with cancer. Cell. 2020;183:1901–1912.e9. - PMC - PubMed
    1. Abdul‐Jawad S, Baù L, Alaguthurai T, del Molino del Barrio I, Laing AG, Hayday TS, et al. Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus‐2 infected cancer patients. Cancer Cell. 2021;39:257–275.e6. - PMC - PubMed